LAG-3

[Immutep Limited] Immutep Limited announced it has received positive feedback from the European Medicines Agency regarding its clinical development program for lead product candidate, eftilagimod alpha, including the planned Phase III trial in MBC.

[Bristol Myers Squibb] Bristol Myers Squibb announced Marketing Authorization Application (MAA) validation for the LAG-3-blocking antibody relatlimab and nivolumab fixed-dose combination for first-line treatment of adult and pediatric patients with advanced (unresectable or metastatic) melanoma.

[Nature Communications] Scientists positionally identified a polymorphic estrogen receptor binding site that regulated Cd2 expression, leading to female-specific differences in T cell-dependent mouse models of autoimmunity.

[Bristol Myers Squibb] Bristol Myers Squibb announced that the US FDA has accepted for priority review the Biologics License Application for the LAG-3-blocking antibody relatlimab and nivolumab fixed-dose combination, administered as a single infusion, for the treatment of adult and pediatric patients with unresectable or metastatic melanoma.

[British Journal of Cancer] The authors critically discuss current knowledge regarding predictive biomarkers for checkpoint inhibitor-based immunotherapy, highlight the missing/unclear links and emphasise the importance of characterising each neoplasm and its microenvironment in order to better guide the course of treatment.

[iScience] Investigators found that advanced fibrosis patients had higher frequencies of >3 inhibitory receptor co-expression on NK cells.